Naphthonone is an antitussive agent.

KETOCAINE is a local anesthetic.

Sulfonamide derivative Disulfamide was developed as diuretic agent.

Clobenzepam (tarpane) is a drug exhibiting antihistaminic properties.

Metiprenaline was developed as a bronchodilator. Information about the current use of this compound is not available.

Lucimycin (lucensomycin or etruscomycin) is a polyene antibiotic with antimycotic activity. Originally it was isolated from Streptomyces lucensis n. sp.

GALARUBICIN (DA-125) is an anthracycline derivative with anticancer activity, containing fluorine. The mechanism of action of this drug lies in inhibition of nucleic acid synthesis through intercalation with DNA. Because the structure and DNA-intercalating properties of DA-125 are similar to adriamycin, the cytotoxic effects of the two anthracyclines probably have similar biochemical mechanisms. Preclinical studies suggest that it may have greater activity and less cardiac toxicity than adriamycin. In a rodent study, administration of D-125 in higher dose levels (25 to 50 mg/kg) has been shown to result in testicular damage.

FEPENTOLIC ACID is a choleretic agent.

FENPIPRAMIDE is a parasympatholytic agent. As a hydrochloride salt, it is an active ingredient of some veterinary medicinal products used as analgesic drugs or antidotes. FENPIPRAMIDE was formerly used in humans as a spasmolytic in obstetrics.

Proterguride is a highly potent dopamine receptor agonist with a long duration of action patented by Schering A.-G. for the treatment of Parkinsonism, restless leg syndrome, or the prophylaxis of migraine. According to preclinical studies, Proterguride, unlike most dopamine receptor agonist, is suitable for transdermal administration. Especially in the case of dopamine agonists, the transdermal route of administration might become of great clinical importance due to the ability to achieve constant plasma levels and, thus, to imitate the physiological continuous release profile of dopamine. Pulsatile stimulation of dopaminergic receptors as it occurs with oral administration of dopaminergic drugs is considered the cause of treatment-associated motor complications.